{
    "clinical_study": {
        "@rank": "40300", 
        "arm_group": {
            "arm_group_label": "Acthar", 
            "arm_group_type": "Experimental", 
            "description": "Acthar 80mg twice weekly for 6 months.  If endpoint is not reached, duration may be increased to 12 months."
        }, 
        "brief_summary": {
            "textblock": "The goal of this study is to evaluate the benefit of ACTH (Acthar) in reducing proteinuria\n      associated with transplant glomerulopathy in non-diabetic kidney transplant recipients."
        }, 
        "brief_title": "Acthar as Rescue Therapy for Transplant Glomerulopathy in Kidney Transplant Recipients", 
        "completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Proteinuria", 
            "Transplant Glomerulopathy"
        ], 
        "condition_browse": {
            "mesh_term": "Proteinuria"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Kidney transplant recipients with confirmed transplant glomerulopathy on kidney\n             biopsy.\n\n          -  Failed standard therapy (>25% reduction in proteinuria) including maximum use of an\n             ACE inhibitor, ARB, or aldosterone blocker with a goal blood pressure less than\n             130/80 and optimization of their immunosuppression\n\n        Exclusion Criteria:\n\n          -  Diabetes"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 5, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02057523", 
            "org_study_id": "2013-0764"
        }, 
        "intervention": {
            "arm_group_label": "Acthar", 
            "description": "Those interested will be started on Acthar 80mg twice weekly for 6 months.  Those with minor adverse effects such as weight gain, worsening hypertension, or glucose intolerance will have their doses reduced to 40mg twice weekly.  Those with major adverse effects such as allergy or infection will discontinue the medication.  If the primary endpoint of 50% reduction in proteinuria or total proteinuria less than 150mg/day is not reached, therapy may be continued for a total of 12 months.", 
            "intervention_name": "Acthar", 
            "intervention_type": "Drug", 
            "other_name": [
                "Repository Corticotropin Hormone", 
                "Acthar Gel", 
                "Adrenocorticotropic Hormone"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Adrenocorticotropic Hormone", 
                "Hormones", 
                "Beta-Endorphin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 5, 2014", 
        "location": {
            "contact": {
                "email": "sakkina@uic.edu", 
                "last_name": "Sanjeev Akkina, MD", 
                "phone": "312-996-8075"
            }, 
            "contact_backup": {
                "email": "mcampa4@uic.edu", 
                "last_name": "Maya Campara, PharmD", 
                "phone": "312-996-0897"
            }, 
            "facility": {
                "address": {
                    "city": "Chicago", 
                    "country": "United States", 
                    "state": "Illinois", 
                    "zip": "60612"
                }, 
                "name": "University of Illinois at Chicago"
            }, 
            "investigator": {
                "last_name": "Sanjeev Akkina, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Acthar as Rescue Therapy for Transplant Glomerulopathy in Kidney Transplant Recipients", 
        "overall_contact": {
            "email": "sakkina@uic.edu", 
            "last_name": "Sanjeev Akkina, MD", 
            "phone": "312-996-8075"
        }, 
        "overall_contact_backup": {
            "email": "mcampa4@uic.edu", 
            "last_name": "Maya Campara, PharmD", 
            "phone": "312-996-0897", 
            "phone_ext": "1"
        }, 
        "overall_official": {
            "affiliation": "University of Illinois at Chicago", 
            "last_name": "Sanjeev Akkina, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "50% Reduction in Proteinuria or Proteinuria < 150mg/day", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02057523"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Illinois at Chicago", 
            "investigator_full_name": "Sanjeev Akkina", 
            "investigator_title": "Assistant Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "25% Reduction in the MDRD eGFR", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "source": "University of Illinois at Chicago", 
        "sponsors": {
            "collaborator": {
                "agency": "Questcor Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "University of Illinois at Chicago", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2015", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}